Destiny Pharma PLC Result of Annual General Meeting

RNS Number : 1782S

Destiny Pharma PLC

12 June 2024

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Result of Annual General Meeting

 

Brighton, United Kingdom - 12 June 2024 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.

 

The full text of each resolution was included in the notice of the meeting which was made available on the Company's website and posted to shareholders on 9 May 2024. The results for the resolutions will shortly be available on the Investors' section of the Company's website, www.destinypharma.com.

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

 

FTI Consulting

Ben Atwell / Simon Conway / Michael Trace

[phone]

[e-mail]

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late-stage assets: XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGFTMBTMTBBBAI